GSK3B and endometrial cancer: Our FACS analyses showed a G2/M arrest in endometrial cancer cells treated with GSK3β inhibitors, which prompted us to examine the expression of Cyclin B1, a cell cycle regulator that is rapidly up-regulated at G2 and degraded at mid-M-phase [35].